Navigation Links
Liver Cirrhosis-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Liver Cirrhosis-Pipeline Insights, 2014

http://www.reportlinker.com/p02278626/-Liver-Cirrhosis-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Liver Cirrhosis-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Liver Cirrhosis. This report provides information on the therapeutic development based on the Liver Cirrhosis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Liver Cirrhosis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Liver Cirrhosis and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Liver Cirrhosis
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Liver Cirrhosis Overview
- Liver Cirrhosis Pipeline Therapeutics
- Liver Cirrhosis Therapeutics under Development by Companies
- Liver Cirrhosis Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Liver Cirrhosis Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Liver Cirrhosis Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Liver Cirrhosis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Liver Cirrhosis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liver Cirrhosis – Discontinued Products
- Liver Cirrhosis – Dormant Products
- Companies Involved in Therapeutics Development for Liver Cirrhosis
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Liver Cirrhosis, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Liver Cirrhosis Assessment by Monotherapy Products
- Liver Cirrhosis Assessment by Combination Products
- Liver Cirrhosis Assessment by Route of Administration
- Liver Cirrhosis Assessment by Stage and Route of Administration
- Liver Cirrhosis Assessment by Molecule Type
- Liver Cirrhosis Assessment by Stage and Molecule Type
- Liver Cirrhosis Therapeutics – Discontinued Products
- Liver Cirrhosis Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Liver Cirrhosis, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Liver Cirrhosis Assessment by Monotherapy Products
- Liver Cirrhosis Assessment by Combination Products
- Liver Cirrhosis Assessment by Route of Administration
- Liver Cirrhosis Assessment by Stage and Route of Administration
- Liver Cirrhosis Assessment by Molecule Type
- Liver Cirrhosis Assessment by Stage and Molecule Type

To order this report: Liver Cirrhosis-Pipeline Insights, 2014
http://www.reportlinker.com/p02278626/-Liver-Cirrhosis-Pipeline-Insights-2014.html
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


 


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Liver Diseases-Pipeline Insights, 2014
2. Liver Fibrosis-Pipeline Insights, 2014
3. Liver Transplantation-Pipeline Insights, 2014
4. BioDelivery Sciences to Ring The NASDAQ Stock Market Opening Bell
5. Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan
6. Needle-Free Delivery: Technology and Market Forecast 2014-2024
7. Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org
8. Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis
9. Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients
10. ResMeds New AirSense 10 CPAP and APAP Devices Deliver Superior Patient Comfort and Cost-Saving Efficiency for Healthcare Providers
11. Coloplast Delivers On Ambitious Targets With Solid Interim Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Technique, Repair Procedure By Technique, By Region, By Country (2016-2021)" ... ... at a CAGR of 13.35% during 2016-2021 The strong ... growth in population with heart disease and rising advances in minimally ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... -- Summary Global Markets ... Primary Hyperoxaluria - Pipeline Review, H1 2017, provides ... System And Sex Hormones) pipeline landscape. Primary ... kidney and bladder stones. It results from the ... blood in the urine, pain when urinating, fever, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
(Date:3/23/2017)... New York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are ... every 3 kids do not brush their teeth the minimum two times a day that ... teeth; with students missing 51 million hours of school and adults missing 164 million hours ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
(Date:3/23/2017)... ... 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle ... , “We’re excited to be operating on U.S. shores, where most of our initial ...
Breaking Medicine News(10 mins):